Drug intelligence / Profile preview

BL1332

Development stage: Phase 2
Lead developer: Bausch + Lomb
Modality: Small Molecules
Administration: Topical Ophthalmic

Overview

BL1332 is an investigational ophthalmic solution being developed for topical use as eye drops. It is undergoing clinical evaluation for its safety, tolerability, and pharmacokinetics in healthy volunteers. The therapeutic areas of interest include eye diseases and nervous system diseases, likely related to ocular pain or similar indications. The mechanism of action and precise molecular target have not been publicly disclosed as of Phase 1 clinical development. The drug was initially developed by Bausch & Lomb.

Other names: BL-1332BL1332BL 1332

Beyond the preview

Go deeper on BL1332.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BL1332.

Explore the full profile